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Effect of visit-to-visit blood pressure variability on cognitive and 
functional decline in mild to moderate Alzheimer's disease. 
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Abstract 
 
Introduction: Visit-to-visit blood pressure (BP) variability (VVV) is increasingly 
recognized as a marker of cardiovascular risk. Although implicated in cognitive 
decline, few studies are currently available assessing its effects on established 
dementia. 
 
Objective: To investigate if VVV is associated with one-year rate of decline in 
measures of cognition and function in patients with mild to moderate Alzheimer’s 
disease (AD) in the Doxycycline And Rifampicin for Alzheimer’s Disease study. 
 
Methods: Patients were included if ≥3 BP readings were available (n=392). VVV was 
defined using different approaches including the coefficient of variation (CV) in BP 
readings between visits. Outcomes included rates of decline in the Standardized 
Alzheimer’s Disease Assessment Scale–Cognitive Subscale (SADAS-cog), Standardised 
MMSE, Clinical Dementia Rating Scale, the Quick Mild Cognitive Impairment screen 
and the Lawton-Brody activities of daily living (ADL) scale.  
 
Results: Half of the patients (196/392) had a ≥4-point decline in the SADAS-cog over 
one-year. Using this cut-off, there were no statistically significant associations 
between any measures of VVV, for systolic or diastolic BP, with and without 
adjustment for potential confounders including treatment allocation, history of 
hypertension and use of anti-hypertensive and cognitive enhancing medications. 
Multiple regression models examining the association between systolic BP CV by 
quartile and decline over one-year likewise showed no clinically significant effects, 
apart from a U-shaped pattern of ADL decline of borderline clinical significance.   
 
Conclusions: This observational study does not support recent research showing that 
VVV predicts cognitive decline in AD. Further studies are needed to clarify its effects 
on ADL in AD.   
 
Key words: Visit-visit-variability, blood pressure variability, blood pressure, 
cognition, Alzheimer’s disease  
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Introduction 
Hypertension is associated with cerebrovascular disease and cognitive impairment 
[1,2], particularly among older people [3]. While there is some evidence that 
treatment of high blood pressure (BP) in those without cerebrovascular disease can 
prevent cognitive decline [4,5], there is growing evidence that raised and fluctuating 
BP are linked with a higher burden of white matter changes and subsequent 
cognitive decline [6,7]. While unclear, the mechanism is likely to be multifactorial, 
relating to the development of small vessel ischemia, compromised cerebral 
autoregulation [6] and the abnormal accumulation of amyloid beta [7].  
 
Visit-to-visit blood pressure variability (VVV), fluctuations in BP readings across 
outpatient visits [8], is linked to atherosclerosis [9,10] and coronary heart disease 
[11].  A recent systematic review and meta-analysis of the effect of VVV suggests 
there are also associations with cardiovascular disease and all-cause mortality, albeit 
these are modest and limited by available data [12]. Persons with dementia have 
greater variability in VVV than aged-matched controls [13]. More recently, high VVV 
has also been associated with cognitive decline in Alzheimer’s disease [14,15] and in 
those without established dementia [16] but not in fronto-temporal dementia [15] 
or with incident all-cause dementia [17] in community-dwelling older adults. Similar 
to its effects on stroke, it is implicated in the development of atherosclerosis and 
arterial stiffness that may ultimately lead to cognitive decline [18,19].  
 
However, studies examining the effects of hypertension and BP variability on 
cognition are limited in number [20] and by the sensitivity and specificity of the 
instruments used to measure change, particularly the Mini-Mental State 
Examination (MMSE) [21], which has ceiling effects and is influenced by age, 
ethnicity, and education [22,23,24]. Data available are confined to observational 
cohort studies [14,15] or in samples without clearly established dementia. Further, 
to our knowledge, no studies have examined the effects of VVV on functional 
outcomes such as personal and instrumental activities of daily living (ADL) and 
global measures of socialisation, community affairs and hobbies in those with 
dementia, which are considered more important patient-centred outcomes that are 
frequently under-reported in dementia trials [25, 26].  
 
Given these concerns, the aim of this study is to examine the effect of VVV on 
detailed, validated cognitive, ADL and global functional measures in those with 
established dementia using data from a completed randomised controlled trial (RCT) 
of patients with mild to moderate stage Alzheimer’s disease (AD), followed over one 
year called the Doxycycline And Rifampicin for Alzheimer’s Disease (DARAD) RCT 
[27].  
 
Methods 
Overview of the DARAD trial  
Data collection  
This analysis included data from the DARAD trial [27]. The methods of the DARAD 
have been reported elsewhere [27,28] but in summary, the DARAD was a multi-
centre, blinded, RCT, conducted in 14 geriatric outpatient clinics in Canada between 
2006 and 2010, comparing two antibiotics, doxycycline and rifampicin, to placebo to 
investigate if these can delay progression in mild to moderate stage AD over one 
year. AD was diagnosed according to National Institute of Neurological and 
Communicative Disorders and Stroke criteria [27]. Those with established AD, aged 
≥50 years, with adequate English language literacy and a Standardised MMSE 
(SMMSE) score between 14–26 out of 30 points (inclusive) were included. 
Neuroimaging with computed tomography (CT), ECG and laboratory testing were 
conducted to support inclusion and exclusion criteria. A sub-study, the DARAD-MRI, 
recruited 58 participants comparing magnetic resonance imaging (MRI) pre and post-
treatment (ClinicalTrials.gov – NCT00692588). Only those with significant 
cerebrovascular disease or multi-infarct dementia, which is demonstrable on CT, 
were excluded. In total, 406 participants were randomized of whom 365 completed 
follow-up [27]. Full details of participant recruitment are available at 
www.controlled-trials.com –ISRCTN15039674 [24]. 
 
Outcome measures included in the DARAD 
Assessments in the DARAD were performed at baseline, 3, 6, 9 and 12 months. 
Systolic and diastolic BP readings were recorded by a trained, dedicated research 
nurse at each visit, while sitting after five minutes rest using the same standard 
mercury sphygmomanometer. Available data included participants’ age, gender, 
years of education and use of anti-hypertensives, cholinesterase inhibitors and or 
memantine. The co-primary outcomes were the Standardized Alzheimer’s Disease 
Assessment Scale–Cognitive Subscale (SADAS-cog) [29] and the Clinical Dementia 
Rating Scale Sum of the Boxes (CDR-SB) [30]. Secondary outcomes included the 
Lawton-Brody ADL scale [31], the Quick Mild Cognitive Impairment (Qmci) screen 
[32], the Geriatric Depression Scale (GDS) [33], and the Cornell Scale for Depression 
in Dementia (CSDD) [34]. The SADAS-cog, CDR-SB, Qmci screen, SMMSE and Lawton-
Brody scale were used in this analysis.  
 
The SADAS-cog is composed of 11 subtests providing a score from 0–70; results ≥13 
suggest impaired cognitive function. Elements include naming, commands, 
construction, orientation, word recognition, language, comprehension, word finding 
and recall. A four-point change in the SADAS-cog at six-months is taken by the US 
Food and Drug Administration to be the minimal important change required to 
confirm the benefit of any new medication [35]. The CDR-SB is a global cognitive 
measure incorporating memory, orientation, judgement and problem solving, 
community affairs, home and hobbies, and personal care domains. It is scored from 
0–18 with higher scores indicating greater cognitive impairment [30]. The Lawton-
Brody ADL scale combines basic (ability to toilet, feed, dress, groom, bathe and walk) 
and instrumental (ability to shop, prepare food, perform housekeeping, wash 
laundry, arrange transport, administer medication, use a telephone and manage 
finances) ADLs across 14 categories and is scored from 14–64 points, where higher 
scores denote greater independence. The Qmci screen is a short cognitive screen, 
sensitive and specific in differentiating mild cognitive impairment and mild dementia 
from normal cognition, scored from 0–100 points, where lower scores indicate 
cognitive impairment incorporating six subtests: orientation, working memory, 
verbal fluency, clock drawing, delayed recall and logical memory [36,37]. It can be 
substituted for SADAS-cog in clinical trials [38] and is widely validated [37, 39-43]. 
 
Analysis in this study 
Visit-to-visit blood pressure variability  
This study examined the effect of VVV on outcomes recorded within the DARAD trial. 
As no single approach to measuring VVV is currently accepted [8], we compared five 
recognized models [8] including the: (1) Standard Deviation (SD); (2) Coefficient of 
Variation in BP readings between visits (CV) calculated as the SD divided by mean BP 
over all available visits expressed as a percentage; (3) variation in BP independent of 
the mean (VIM), a transformation of SD uncorrelated to mean BP; (4) Average real 
variability (ARV); the average of absolute differences between successive BP 
measurements; (5) Delta BP defined as the maximum BP minus minimum BP.  
[8]. In general, these measures are strongly correlated and it is recommended that at 
least one metric of overall BP variability (SD, CV or VIM), variability between 
concentric visits (ARV) and of single extreme values (Delta BP) be included in the 
analysis [44]. These were calculated for both systolic and diastolic BP readings. Only 
participants with three or more interval BP readings available were included in this 
analysis. Missing data were not imputed. 
 
Main analysis 
Data were analysed using SPSS V25.0 (SPSS Inc., Chicago IL, USA). Data were 
normally distributed and analysed with parametric statistical approaches. Cognitive 
decline was calculated based on the change in each instrument over one year based 
on the difference between baseline and last available follow-up scores. Each 
measure of VVV was examined in turn as the independent variable. First, binary 
logistic regression was used to examine the association between SADAS-cog data, 
dichotomized into <4 or ≥4 points, considered a clinically important change [35], 
categorical outcomes and measures of VVV. Second, linear regression analysis was 
performed to explore the association between VVV and change in cognitive and 
functional scores as continuous variables. Cognitive and functional outcome 
measures were taken as the dependent variable (Model one).  
 
Sensitivity analysis 
Results were then adjusted for potential covariates in a sensitivity analysis; Model 2 
controlling for sex, age, and educational level (<12 or ≥12 years) and Model 3 for the 
GDS, investigational product received (i.e. treatment allocation of either rifampicin 
and/or doxycycline or placebo), anti-hypertensive treatment, patient’s average BP 
and use of cholinesterase inhibitors and/or memantine. An alternative sensitivity 
analysis (Model 3b), adjusting for baseline SMMSE, treatment allocation, depression 
(GDS and CSDD), the use of cognitive enhancers (cholinesterase inhibitors and/or 
memantine) and the use of centrally-acting angiotensin converting enzyme receptor 
inhibitors (ACEi) versus none, was conducted (see Appendix). The later was added as 
ACEis were the most commonly prescribed anti-hypertensive in this sample and our 
previous study showed that centrally-acting ACEi slowed functional and cognitive 
decline in this cohort [28]. There were insufficient numbers of other classes of anti-
hypertensives available including Angiotensin II receptor blockers (ARBs), to conduct 
a similar sensitivity analysis with these agents. To investigate the differential effects 
of minimum and maximum BP, participants were divided into mutually exclusive 
quartiles (Q) based on their systolic BP CV values: Q1 ≤5.9; Q2 6.0 – 8.3; Q3 8.4 – 
10.7; Q4 ≥10.8. Multiple regression using ANOVA analysis was performed for Model 
1, and ANCOVA for Models 2, 3 and 4. In a further sensitivity analysis, CV values 
were also divided into quintiles. CV was selected for this sub-analysis as it is 
independent of mean BP and is consistent with other studies allowing comparison 
[11,17]. 
 
Results 
Characteristics of patients included in this analysis 
Of the 406 participants available from the DARAD trial, 392 (97%) had at least three 
BP measurements over follow-up and were included in this analysis. The mean age 
of these was 77.67 years, standard deviation (SD) ±7.09 years; 49% were female. In 
all, 219 (56%) were hypertensive, 357 (91%) taking cholinesterase inhibitors and 60 
(15%) memantine. There were no statistically significant differences in potentially 
cognitively enhancing medications, cholinesterase inhibitors (p=0.61) or memantine 
(p=1.0), gender (p=0.60) or years in education (p=0.93) between those included and 
those excluded from the analysis. Excluded participants were significantly older 
(p=0.004) but this was not clinically meaningful, both with a mean age of 77 years. 
The characteristics of participants included compared to those excluded and all 
patients recruited to the DARAD trial are presented in Table 1. The mean number of 
BP readings per participant included was 5.53 ±0.88. Mean systolic BP at baseline 
was 134.17 ±16.12 mmHg and 132.39 ±17.29 mmHg at the last available follow-up. 
Mean diastolic BP was 72.92 ± 10.30 mmHg at baseline compared to 72.59 ±10.59 
mmHg at end-point. The mean CV of systolic BP was 8.77 ±3.85 versus 10.52 ±5.11 
for diastolic BP.  
 
Effect of VVV on cognitive and functional outcomes 
At one year, 196/392 (50%), half of the sample had an increase of ≥4 points in the 
SADAS-cog (denoting cognitive decline). Binary logistic regression using the SADAS-
cog as the categorical dependent variable, taking a deterioration of four points as 
clinically important [35], showed that there were no statistical associations between 
any of the measures of VVV, for either systolic or diastolic BP, with and without 
adjustment, and decline in the SADAS-cog during follow-up. The odds ratio for each 
was close to or equal to 1.0 as can be seen in Table 2. Examining the mean CV 
systolic and diastolic BP by quartile on change in the SADAS-cog showed no gradient 
effect with 95% CI all including the null. Using linear regression, examining each of 
the outcomes of interest in turn (i.e. SADAS-cog, CDR-SB, Lawton-Brody ADL scale, 
Qmci screen and SMMSE scores as continuous variables), similarly showed no 
statistically significant association with any of the measures of VVV. Sensitivity 
analysis showed that variables including the use of cholinesterase inhibitors, 
memantine and anti-hypertensives (any versus none), see models 2 and 3 above, did 
not influence these results,  except for a weak but statistically significant association 
between reduced decline in Lawton-Brody ADL scale scores and systolic BP using 
Delta BP as a marker of VVV in model 3. All other reported coefficients were non-
significantly different from 0, see Table 3. Adjusting for baseline cognition based on 
SMMSE scores and centrally versus non-centrally acting ACEis in Model 3b 
reaffirmed that there were no significant associations (see Appendix).  
 
Proportions of cognitive and functional decline 
To assess the effects of minimal and maximal systolic BP we compared participants 
according to systolic BP CV values by quartiles using Q1 as the reference. The 
proportion with a ≥4 points increase in the SADAS-cog by BP CV quartile is presented 
in Figure 1; no statistically significant differences were seen for either systolic 
(p=0.54) or diastolic (p=0.27) readings (Table 2). Although Q2 of diastolic BP CV 
quartile was found to approach significance in model 1 (p=0.054) it was not 
statistically significant in model 2 (p=0.056) or model 3 (p=0.057) either. Multiple 
linear regression models showed no association between systolic blood pressure CV 
quartiles and each cognitive and functional outcome except for those in the third 
quartile with a CV in systolic BP of between 8.4 – 10.7, who had a significantly 
greater rate of decline in ADL compared to those in Q1. These data are presented in 
Table 4 and in Figure 2.  However, there were no overall statistically significant 
differences in the rate of decline in ADL scores comparing all quartiles and this effect 
was lost when BP was divided into quintiles (see Table 5 in the Appendix). 
Otherwise, for unadjusted and adjusted models, no other significant results were 
found for any of the cognitive or functional outcome measures assessed.  
 
Discussion 
Overview 
This study presents an examination of VVV in patients with established dementia 
participating in a RCT investigating rate of cognitive and functional decline after 
treatment with doxycycline or rifampin, alone or in combination, over one year. The 
findings of this observational secondary analysis do not suggest that VVV is 
associated with either cognitive or functional decline in those with mild to moderate 
stage AD. Similarly, the results do not suggest that low or high VVV predicts one-year 
change in scores. Irrespective of the approach to calculating VVV, no clinically 
significant association with rate of decline using a selection of validated outcome 
measures was consistently found for either systolic or diastolic BP. Sensitivity 
analysis showed that a wide variety of independent variables including use of any 
anti-hypertensive medication and cholinesterase inhibitors or memantine, did not 
influence associations.  Data were also adjusted for depression as this may interact 
with systolic BP variability to hasten cognitive decline [45]. A small difference in rates 
of decline in ADL (for overall systolic BP delta and CV in the third quartile when these 
were examined by quartile) were of statistical significance. This may suggest that 
further research is needed to explore the effects of VVV on ADL, particularly as there 
is some evidence that higher VVV in systolic but not diastolic BP is associated with an 
increased rate of functional decline in ADL in older adults without established 
dementia [46]. Further, the results suggest a possible U-shaped association with 
more marked decline in ADL in those with higher and lower quartiles compared to 
the middle quartile (Q3), similar to a recent study showing this increases mortality in 
patients with cardiovascular disease [47]. However, as these changes were not seen 
for cognition and were lost when CV values were examined as quintiles, it is 
probable that they relate to multiplicity, although further exploration is needed.  
 
Results in context 
These results differ from those found in other observational studies of persons with 
mild-moderate stage AD with a similar age profile, which have found that BP VVV 
(specifically systolic BP variability) was associated with significant differences in 
decline in the MMSE over one year [14,15]. However, this to our knowledge is one of 
only a few studies investigating this and the first to examine the impact of VVV on 
cognition using more detailed neuropsychological testing including the standardized 
ADAS-cog, used by many regulatory authorities including the Food and Drug 
Administration in the United States to denote clinically meaningful change in 
dementia trials [35]. It is also the first to examine the effect on ADL. Other possible 
reasons that may account for the differences include the MMSE score at entry and 
differences in patient selection. While these results differ from the studies by 
Lattanzi et al [14,15], they do reflect the current lack of certainty regarding the 
significance of VVV for all cardiovascular outcomes [12]. To date, while there is data 
from meta-analysis showing that VVV is associated with increased mortality and 
incidence of cardiovascular disease and stroke, samples are heterogenous [12, 
48,49], only modest supportive evidence is available [12, 49] and further studies are 
recommended to determine its significance [14] and confirm if there is any effect in 
established AD [20] or other dementia subtypes. Some recent studies including a 
post hoc analysis of the Systolic Blood Pressure Intervention (SPRINT) RCT have 
found no association between VVV in office BP and a composite end-point of fatal 
and nonfatal cardiovascular events, though these did not look at the effects of 
cognition [50]. Finally, it is suggested that older patients with established 
cerebrovascular disease and more cardiovascular co-morbidity may already be too 
advanced to detect the effects of VVV on dementia [17, 20]. 
 
Strengths and limitations 
The strengths of this study include the RCT design with a relatively large sample size 
compared to other studies examining rate of cognitive decline in dementia, the 
standardisation of measurements, high rates of compliance with medications and 
measurement and relatively low loss to follow-up [27]. Further, the study included a 
range of cognitive and functional measures including the CDR-SB, allowing for more 
detailed investigation of the effects of VVV on those with mild to moderate AD than 
existing studies [14,15]. While the inclusion of a range of dependent variables, which 
were shown to have moderate to strong correlation with each other [38], could have 
increased the possibility of chance findings of significance, that it did not, serves to 
highlight the lack of association between VVV and decline in these patients. 
Limitations include the observational nature of the study and the relatively short-
period of follow-up, one year (the duration of the DARAD trial was informed by a 
pilot RCT that showed possible benefits at one year [51]); it is possible that 
significant associations could be demonstrated over longer periods. This said, most 
studies in this area have used an observational design [20] and the only two 
comparable studies included smaller numbers, approximately 240 patients with AD 
in each, followed over a similar period, with patients who were not recruited within 
the framework of a rigorously controlled RCT [14,15]. In addition, the diagnosis of 
AD, while robust, did not include the routine use of MRI or biomarkers meaning that 
some patients with concomitant mild cerebrovascular changes could have been 
included.  That said, patients underwent a comprehensive work-up including 
neuroimaging with CT in all cases, laboratory testing and detailed neuropsychological 
testing meeting established clinical criteria for AD at the time of testing [27] and a 
proportion had an MRI pre and post treatment as part of the DARAD-MRI sub-study 
[52]. The co-existence of AD and minor cerebrovascular changes is common, does 
not appear to affect rate of progression [53] and is often acceptable for inclusion in 
trials of AD where it does not affect the diagnostic classification [54]. This is arguably 
more naturalistic and representative of ‘real-life’ clinical practice. The study was 
conducted in a single country, Canada, and no data on ethnicity were available, 
reducing the generalizability of results. However, Canada is a large, multi-ethnic 
country, where in 2011 the majority were Caucasian, 19.1% were visible minorities 
(South Asian, Chinese, Black) and 4.3% Aboriginal Canadians [55]. Those with 
clinically significant comorbidities including poorly controlled diabetes were 
excluded, further, restricting generalizability. The adjustment for anti-hypertensives 
is limited to the presence or absence of any agent or central versus non-centrally 
acting ACEis. Insufficient numbers of other anti-hypertensives including ARBs, which 
were less commonly prescribed during the recruitment window of this trial, were 
available for analysis. However, adjusting for multiple anti-hypertensives may lead to 
collinearity and some of the most robust data exists for agents targeting the renin 
angiotensin aldosterone system [56]. Further, details of historical anti-hypertensive 
therapy were not available. Finally, the number and timing of visits and device used 
to measure BP can affect VVV, potentially influencing results and comparability 
between studies [57].  
 
Conclusion 
In summary, this observational study showed that there were few statistically 
significant effects of VVV or high VVV, irrespective of the approach used to define it, 
on a range of cognitive and functional outcomes in those with confirmed AD 
recruited to a RCT over one-year. Further studies are now required using prospective 
longitudinal cohort designs following patients over longer periods of time and 
examining different populations to confirm whether VVV is a marker of risk of 
decline in those with established dementia, if it results in worse 
cardiovascular outcomes and whether treatment could be beneficial.   
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Tables 
 
Table 1. Baseline characteristics of participants included in this analysis from the Doxycycline 
And Rifampicin for Alzheimer’s Disease (DARAD) study (n=392) compared to all (n=406) 
included in the DARAD trial. 
 
 
Variable Total 
(N=406) 
(Mean±SD or %) 
Included 
(n=392) 
(Mean±SD or %) 
Not included 
(n=14) 
(Mean±SD or %) 
*p-value  
Age (years) 77.86 ± 7.13 77.67 ± 7.09 83.21 ± 6.41 0.004 
Gender (% female) 49% 49% 57% 0.60 
Education (years) 12.31 ± 3.47 12.31 ± 3.48 12.00 ± 0.00 0.93 
Hypertension (%) 54% 56% 50% 1.00 
Systolic Blood pressure (mmHg) 134.20 ± 16.01 134.17 ± 16.12 135.00 ± 12.84 0.86 
Diastolic Blood pressure (mmHg) 73.05 ± 10.27 72.92 ± 10.30 76.92 ± 8.79 0.17 
CV of Systolic BP (expressed as (%) 8.61 ± 3.94 8.77 ± 3.85 4.21 ± 4.00 < 0.001 
CV of Diastolic BP (expressed as %) 10.34 ± 5.20 10.52 ± 5.11 5.50 ± 5.51 < 0.001 
Use of anti-hypertensive (%) 94% 94% 100% 1.00 
Use of metformin (%) 6.5% 6.4% 7.1% 1.00 
Cholinesterase inhibitor use (%) 91% 91% 100% 0.61 
Memantine use (%)  15% 15% 14% 1.00 
SADAS-cog 21.68 ± 7.89 21.67 ± 7.86 22.00 ± 8.85 0.88 
CDR-SB 5.89 ± 2.50 5.83 ± 2.47 7.54 ± 2.61 0.012 
SMMSE 22.15 ± 3.12 22.15 ± 3.14 22.21 ± 2.69 0.94 
Qmci screen 38.47 ± 12.86 38.52 ± 12.81 37.00 ± 14.66 0.66 
Lawton-Brody ADL 50.03 ± 6.82 50.28 ± 6.65 42.93 ± 8.10 < 0.001 
CSDD 3.53 ± 3.12 3.52 ± 3.13 4.00 ± 0.00 0.88 
GDS 1.79 ± 1.87 1.78 ± 1.87 4.00 ± 0.00 0.24 
ADL= Activities of daily living; BP = Blood pressure; CDR-SB; CSDD = Cornell Scale for Depression in Dementia; CV = Coefficient of 
variation; GDS = Geriatric Depression Scale; Qmci screen = Quick Mild Cognitive Impairment screen; SADAS-cog =; SMMSE = 
Standardised Mini-Mental State Examination;  
* Comparison of patients included in this analysis compared to the total included in the DARAD  
 
Table 2. Binary logistic regression models (adjusted and unadjusted) showing the association 
between measures of Visit-Visit BP (Blood Pressure) Variability (VVV) and change (increase ≥ 
4 points) in the Standardized Alzheimer’s Disease Assessment Scale–Cognitive Subscale.  
 
VVV 
 
Model 1  
(unadjusted) 
OR with 95% CI 
Model 2  
(adjusted*)  
OR with 95% CI 
Model 3  
(adjusted**)  
OR with 95% CI 
Sy
st
ol
ic 
BP
 CV 0.99 (0.93 to 1.05) 1.00 (0.94 to 1.06) 0.99 (0.93 to 1.05) 
SD 0.99 (0.95 to 1.03) 0.99 (0.95 to 1.04) 0.99 (0.95 to 1.04) 
VIM 0.99 (0.95 to 1.03) 1.00 (0.95 to 1.04) 0.99 (0.95 to 1.04) 
ARV 1.00 (0.97 to 1.03) 1.00 (0.97 to 1.04) 1.00 (0.97 to 1.04) 
Delta 1.00 (0.98 to 1.02) 1.00 (0.98 to 1.02) 1.00 (0.98 to 1.02) 
Di
as
to
lic
 B
P CV 1.01 (0.97 to 1.06) 1.02 (0.97 to 1.06) 1.01 (0.97 to 1.06) 
SD 1.02 (0.96 to 1.08) 1.02 (0.96 to 1.08) 1.02 (0.96 to 1.09) 
VIM 1.02 (0.96 to 1.08) 1.02 (0.96 to 1.08) 1.02 (0.96 to 1.09) 
ARV 1.01 (0.97 to 1.06) 1.01 (0.97 to 1.06) 1.02 (0.97 to 1.07) 
Delta 1.00 (0.98 to 1.03) 1.00 (0.98 to 1.03) 1.00 (0.98 to 1.03) 
Sy
st
ol
ic 
BP
 
CV
 q
ua
rt
ile
s Q1 (≤ 5.9) reference reference reference 
Q2 (6.0 - 8.3) 1.29 (0.71 to 2.37) 1.27 (0.69 to 2.34) 1.27 (0.68 to 2.38) 
Q3 (8.4 - 10.7) 1.33 (0.72 to 2.43) 1.41 (0.76 to 2.60) 1.36 (0.72 to 2.56) 
Q4 (≥ 10.8) 0.95 (0.51 to 1.77) 1.03 (0.55 to 1.94) 0.96 (0.51 to 1.81) 
Di
as
to
lic
 B
P 
CV
 q
ua
rt
ile
s Q1 (≤ 6.9) reference reference reference 
Q2 (7.0 - 9.8) 1.83 (0.99 to 3.38) ^ 1.83 (0.98 to 3.39)  1.86 (0.98 to 3.51)  
Q3 (9.9 - 12.9) 1.55 (0.84 to 2.85) 1.55 (0.84 to 2.87) 1.46 (0.78 to 2.73) 
Q4 (≥ 13) 1.42 (0.77 to 2.62) 1.44 (0.78 to 2.69) 1.38 (0.73 to 2.62) 
CV = Coefficient of Variation; SD = Standard Deviation; VIM = Variation Independent of Mean; ARV = Average real variability; 
^ Borderline statistical significance (p = .054) 
*Model 2: adjusted for sex, age, education (<12 or ≥12 years). 
**Model 3: adjusted for anti-hypertensive, treatment group (placebo, rifampicin and/or doxycycline), use of cholinesterase inhibitors 
or memantine, Geriatric Depression Scale, patient’s average blood pressure.  
Note: Reported as Odd Ratio (OR) with 95% Confidence Intervals (CI).  
 
 
 
Table 3. Linear regression models (adjusted and unadjusted) for an association between 
measures of Visit-Visit BP Variability and change in scores of the Standardized Alzheimer’s 
Disease Assessment Scale–Cognitive Subscale (SADAS-cog), Clinical Dementia Rating Scale- 
Sum of Boxes (CDR-SB), Quick Mild Cognitive Impairment (Qmci) Screen and Lawton-Brody 
Activities of Daily Living Scale and Standardised Mini-Mental State Examination (SMMSE). 
 
Instrument Visit-Visit BP 
Variability 
Model 1  
(unadjusted) 
Model 2  
(adjusted*) 
Model 3  
(adjusted**) 
SADAS-cog 
Sy
st
ol
ic 
BP
 CV 0.02 (-0.20 to 0.24) 0.05 (-0.17 to 0.27) 0.02 (-0.20 to 0.24) 
SD -0.01 (-0.17 to 0.15) 0.01 (-0.15 to 0.17) -0.01 (-0.15 to 0.18) 
VIM 0.003 (-0.16 to 0.17) 0.02 (-0.14 to 0.19) 0.02 (-0.15 to 0.18) 
ARV -0.01 (-0.12 to 0.11) 0.01 (-0.11 to 0.13) 0.02 (-0.10 to 0.13) 
Delta 0.01 (-0.05 to 0.07) 0.02 (-0.04 to 0.08) 0.02 (-0.04 to 0.08) 
Di
as
to
lic
 B
P 
CV -0.02 (-0.18 to 0.14) -0.02 (-0.18 to 0.15) 0.001 (-0.16 to 0.16) 
SD -0.001 (-0.22 to 0.22) -0.002 (-0.22 to 0.22) 0.02 (-0.21 to 0.24) 
VIM -0.01 (-0.24 to 0.21) -0.01 (-0.24 to 0.21) 0.01 (-0.22 to 0.23) 
ARV 0.01 (-0.16 to 0.18) 0.02 (-0.15 to 0.19) 0.04 (-0.13 to 0.21) 
Delta 0.01 (-0.07 to 0.10) 0.01 (-0.07 to 0.10) 0.02 (-0.06 to 0.11) 
 
CDR-SB 
Sy
st
ol
ic 
BP
 CV 0.04 (-0.04 to 0.12) 0.03 (-0.05 to 0.11) 0.02 (-0.06 to 0.10) 
SD 0.02 (-0.04 to 0.07) 0.01 (-0.05 to 0.07) 0.02 (-0.04 to 0.08) 
VIM 0.02 (-0.04 to 0.08) 0.02 (-0.04 to 0.08) 0.02 (-0.04 to 0.08) 
ARV 0.01 (-0.03 to 0.05) 0.01 (-0.04 to 0.05) 0.01 (-0.03 to 0.06) 
Delta 0.01 (-0.01 to 0.03) 0.01 (-0.01 to 0.03) 0.01 (-0.01 to 0.03) 
Di
as
to
lic
 B
P CV 0.02 (-0.05 to 0.08) 0.01 (-0.04 to 0.07) 0.01 (-0.05 to 0.07) 
SD 0.01 (-0.07 to 0.09) 0.01 (-0.07 to 0.09)  0.02 (-0.06 to 0.10) 
VIM 0.02 (-0.07 to 0.10) 0.01 (-0.07 to 0.09) 0.02 (-0.07 to 0.10) 
ARV 0.04 (-0.02 to 0.10) 0.04 (-0.02 to 0.10) 0.05 (-0.02 to 0.11) 
Delta 0.01 (-0.02 to 0.04) 0.01 (-0.02 to 0.04) 0.01 (-0.02 to 0.04) 
 
Lawton-
Brody ADL 
Scale 
Sy
st
ol
ic 
BP
 CV -0.14 (-0.33 to 0.04) -0.14 (-0.33 to 0.04) -0.14 (-0.33 to 0.04) 
SD -0.09 (-0.23 to 0.04) -0.09 (-0.23 to 0.05) -0.11 (-0.25 to 0.03) 
VIM -0.10 (-0.24 to 0.03) -0.10 (-0.24 to 0.04) -0.11 (-0.25 to 0.03) 
ARV -0.04 (-0.14 to 0.06) -0.05 (-0.15 to 0.05) -0.06 (-0.16 to 0.04) 
Delta -0.05 (-0.09 to 0.004) -0.04 (-0.09 to 0.006) -0.05 (-0.10 to -0.002)*** 
Di
as
to
lic
 B
P CV 0.02 (-0.12 to 0.16) 0.03 (-0.11 to 0.16) 0.04 (-0.10 to 0.18) 
SD 0.04 (-0.14 to 0.23) 0.05 (-0.14 to 0.24) 0.04 (-0.15 to 0.23) 
VIM 0.04 (-0.15 to 0.23) 0.04 (-0.15 to 0.23) 0.05 (-0.14 to 0.24) 
ARV 0.05 (-0.10 to 0.19) 0.05 (-0.10 to 0.19) 0.04 (-0.11 to 0.18) 
Delta 0.01 (-0.06 to 0.08) 0.02 (-0.06 to 0.09) 0.01 (-0.06 to 0.08) 
 
Qmci Screen 
Sy
st
ol
ic 
BP
 CV -0.12 (-0.41 to 0.17) -0.18 (-0.47 to 0.10) -0.18 (-0.47 to 0.12) 
SD -0.09 (-0.31 to 0.12) -0.13 (-0.34 to 0.08) -0.13 (-0.35 to 0.09) 
VIM -0.09 (-0.31 to 0.12) -0.14 (-0.35 to 0.08) -0.13 (-0.35 to 0.09) 
ARV -0.05 (-0.20 to 0.10) -0.07 (-0.23 to 0.08) -0.07 (-0.23 to 0.08) 
Delta -0.04 (-0.12 to 0.04) -0.06 (-0.13 to 0.02) -0.06 (-0.14 to 0.02) 
Di
as
to
lic
 B
P CV 0.01 (-0.20 to 0.23) 0.001 (-0.21 to 0.21) -0.02 (-0.24 to 0.19) 
SD -0.02 (-0.31 to 0.28) -0.02 (-0.32 to 0.27)  -0.03 (-0.33 to 0.27) 
VIM -0.004 (-0.30 to 0.29) -0.01 (-0.31 to 0.28) -0.03 (-0.33 to 0.27) 
ARV 0.02 (-0.21 to 0.25) -0.003 (-0.23 to 0.22) -0.01 (-0.24 to 0.22) 
Delta -0.03 (-0.14 to 0.09) -0.03 (-0.14 to 0.08) -0.03 (-0.14 to 0.08) 
 
SMMSE 
Sy
st
ol
ic 
BP
 CV -0.05 (-0.16 to 0.06) -0.06 (-0.17 to 0.05) -0.05 (-0.16 to 0.06) 
SD -0.02 (-0.10 to 0.06) -0.02 (-0.11 to 0.06) -0.03 (-0.11 to 0.05) 
VIM -0.03 (-0.11 to 0.06) -0.03 (-0.12 to 0.05) -0.03 (-0.12 to 0.05) 
ARV 0.02 (-0.04 to 0.08) 0.01 (-0.05 to 0.07) 0.01 (-0.05 to 0.07) 
Delta -0.01 (-0.04 to 0.02) -0.02 (-0.05 to 0.02) -0.02 (-0.05 to 0.01) 
Di
as
to
lic
 B
P CV 0.03 (-0.05 to 0.12) 0.03 (-0.05 to 0.11) 0.03 (-0.06 to 0.11) 
SD 0.04 (-0.07 to 0.16) 0.04 (-0.07 to 0.16) 0.03 (-0.08 to 0.15) 
VIM 0.05 (-0.07 to 0.16) 0.05 (-0.07 to 0.16) 0.04 (-0.08 to 0.15) 
ARV 0.03 (-0.06 to 0.12) 0.03 (-0.06 to 0.11) 0.02 (-0.07 to 0.11) 
Delta 0.01 (-0.03 to 0.05) 0.01 (-0.03 to 0.05) 0.01 (-0.04 to 0.05) 
CV = Coefficient of Variation; SD = Standard Deviation; VIM = Variation Independent of Mean; ARV = Average real variability; 
*Model 2: adjusted for sex, age, education (<12 or ≥12 years). 
**Model 3: adjusted for anti-hypertensive, treatment group (placebo, rifampicin and/or doxycycline), use of cholinesterase inhibitors or memantine, Geriatric Depression Scale, 
patient’s average blood pressure. 
Note: Reported values are linear regression coefficients with 95% confidence intervals, all values are non-significant different from 0, except for one coefficient marked with *** 
(p < 0.05). 
Table 4. Multiple linear regression models (adjusted and unadjusted) for an association 
between systolic blood pressure coefficient of variation (CV) quartiles (Q) taking Q1 as the 
reference value and change in scores of the Standardized Alzheimer’s Disease Assessment 
Scale–Cognitive Subscale (SADAS-cog), Clinical Dementia Rating Scale- Sum of Boxes (CDR-
SB), Quick Mild Cognitive Impairment (Qmci) Screen and Lawton-Brody Activities of Daily 
Living Scale.  
 
Dependent variable 
Systolic Blood Pressure CV quartiles  
p value Q1 
≤ 5.9 
Q2 
6.0 – 8.3 
Q3 
8.4 – 10.7 
Q4 
≥ 10.8 
SA
DA
S-
co
g 
ch
an
ge
 
Model 1 0 (ref) 0.36  
(-1.90 to 2.63) 
-0.10 
(-2.37 to 2.17) 
0.10 
(-2.22 to 2.42) 0.75 
Model 2* 0 (ref) 0.33 
(-1.93 to 2.59) 
0.13 
(-2.14 to 2.41) 
0.40 
(-1.93 to 2.74) 0.73 
Model 3** 0 (ref) 0.16 
(-2.12 to 2.44) 
-0.32 
(-2.63 to 1.99) 
0.002 
(-2.34 to 2.35) 0.79 
Qm
ci 
Sc
re
en
 
ch
an
ge
 
Model 1 0 (ref) -0.29  
(-3.26 to 2.67) 
2.69 
(-0.29 to 5.66) 
-1.59 
(-4.63 to 1.46) 0.08 
Model 2* 0 (ref) -0.15 
(-3.09 to2.78) 
2.35  
(-0.61 to 5.31) 
-2.22 
(-5.25 to 0.82) 0.12 
Model 3** 0 (ref) -0.06 
(-3.05 to 2.94) 
2.68 
(-0.36 to 5.72) 
-2.12 
(-5.20 to 0.96) 0.08 
 La
w
to
n-
Br
od
y 
AD
L 
ch
an
ge
 
Model 1 0 (ref) -0.72 
(-2.61 to 1.18) 
-1.86*** 
(-3.76 to -0.01) 
-0.93 
(-2.88 to 1.02) 0.046 
Model 2* 0 (ref) -0.78 
(-2.68 to 1.12) 
-1.94*** 
(-3.85 to -0.03) 
-0.97 
(-2.93 to 0.99) 0.047 
Model 3** 0 (ref) -0.75 
(-2.67 to 1.17) 
-2.03*** 
(-3.98 to -0.08) 
-0.99 
(-2.97 to 0.98) 0.041 
CD
R-
SB
 
 ch
an
ge
 
Model 1 0 (ref) 0.21 
(-0.61 to 1.03) 
0.18 
(-0.64 to 1.00) 
0.30 
(-0.54 to 1.14) 0.48 
Model 2* 0 (ref) 0.25 
(-0.57 to 1.06) 
0.16 
(-0.67 to 0.98) 
0.27 
(-0.58 to 1.11) 0.53 
Model 3** 0 (ref) 0.18 
(-0.65 to 1.01) 
0.05 
(-0.79 to 0.88) 
0.13 
(-0.72 to 0.98) 0.67 
SM
M
SE
 
 ch
an
ge
 
Model 1 0 (ref) 0.04 
(-1.10 to 1.17) 
0.38 
(-0.76 to 1.52) 
-0.41 
(-1.57 to 0.76) 0.49 
Model 2* 0 (ref) 0.06 
(-1.08 to 1.20) 
0.32 
(-0.83 to 1.46) 
-0.54 
(-1.71 to 0.63) 0.36 
Model 3** 0 (ref) 0.26 
(-0.89 to 1.40) 
0.57 
(-0.59 to 1.73) 
-0.35 
(-1.52 to 0.82) 0.33 
*Model 2: adjusted for sex, age, low education (<12 years). 
**Model 3: adjusted for anti-hypertensive, treatment group (placebo, rifampicin and/or doxycycline), use of 
cholinesterase inhibitors or memantine, Geriatric Depression Scale, patient’s average systolic blood pressure.  
*** p<0.05 
Note:  Reported values are linear regression coefficients with 95% Confidence Intervals (CI). 
 
 
 
 
 
 
 
 
Figures 
 
Figure 1. Proportion of patients with a deterioration (≥4 points increase over follow-up) in 
the Standardized Alzheimer’s Disease Assessment Scale–Cognitive Subscale (SADAS-cog) 
according to (a) quartiles of systolic BP CV, (b) quartiles of diastolic BP CV. 
 
  
  a.       b. 
 
 
Figure 2. Development of deterioration in cognition and activities of daily living (ADL) 
according to systolic blood pressure (BP) coefficient of variation (CV) quartiles: decline in (a) 
Standardized Alzheimer’s Disease Assessment Scale–Cognitive Subscale SADAS-cog, (b) 
Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB), (c) Quick Mild Cognitive Impairment 
(Qmci) screen, (d) ADL change during one-year follow-up and (e) Standardised Mini-Mental 
State Examination (SMMSE). 
 
         
  a.                          b. 
 
         
  c.                       d. 
 
 
  e. 
 
Note: results based on linear regression are presented as linear regression with 95% confidence intervals 
adjusted for sex, age, education, randomization group, Geriatric Depression Scale, Standardised Mini-Mental 
State Examination use of anti-hypertensives, cholinesterase inhibitors and memantine, patient’s average systolic 
blood pressure. 
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